ID   PC-9/IR
AC   CVCL_DP47
SY   PC-9-IR; PC9-IR; PC9/IR; PC9IR; PC9/gef
DR   PRIDE; PXD001548
DR   PRIDE; PXD002224
DR   Wikidata; Q54938501
RX   PubMed=26202522;
RX   PubMed=26554430;
RX   PubMed=28290473;
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: EGFR p.Glu746_Ala750del (c.2235_2249del15) (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Arg248Gln (c.743G>A) (from parent cell line).
CC   Omics: Deep membrane proteome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Derived from metastatic site: Lymph node.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 06-09-19; Version: 7
//
RX   PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477;
RA   Kitata R.B., Dimayacyac-Esleta B.R., Choong W.-K., Tsai C.-F.,
RA   Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D.,
RA   Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.;
RT   "Mining missing membrane proteins by high-pH reverse-phase stagetip
RT   fractionation and multiple reaction monitoring mass spectrometry.";
RL   J. Proteome Res. 14:3658-3669(2015).
//
RX   PubMed=26554430; DOI=10.1021/acs.analchem.5b03639;
RA   Dimayacyac-Esleta B.R., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K.,
RA   Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y.,
RA   Chen Y.-J.;
RT   "Rapid high-pH reverse phase stagetip for sensitive small-scale
RT   membrane proteomic profiling.";
RL   Anal. Chem. 87:12016-12023(2015).
//
RX   PubMed=28290473; DOI=10.1038/srep44021;
RA   Wang Y.-T., Pan S.-H., Tsai C.-F., Kuo T.-C., Hsu Y.-L., Yen H.-Y.,
RA   Choong W.-K., Wu H.-Y., Liao Y.-C., Hong T.-M., Sung T.-Y., Yang P.-C.,
RA   Chen Y.-J.;
RT   "Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant
RT   target in non-small cell lung cancer.";
RL   Sci. Rep. 7:44021-44021(2017).
//